CL2A-SN-38 Conjugate Synthesis Yield Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing CL2A-SN-38 conjugates are inefficient with high levels of contaminating by-products and require optimization for improved yield and minimal toxicity, especially in the context of therapeutic immunoconjugates targeting cancer, autoimmune, and infectious diseases.
Innovation Solution
A novel synthetic protocol involving specific reaction steps and conditions, such as using tetrabutylammonium fluoride for desilylation, reduced buffer washes, and avoiding triphenylphosphine in copper-catalyzed reactions, is employed to produce CL2A-SN-38, followed by conjugation with antibodies or peptides using a maleimide moiety, and purification through tangential flow filtration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used to produce CL2A-SN-38 conjugates, then production can proceed with standard protocols, but the yield is low and contaminating by-products are high
Solution Approach 1:
The patent modifies reaction parameters including using tetrabutylammonium fluoride for desilylation instead of conventional methods, reducing buffer washes in purification, and avoiding triphenylphosphine in copper-catalyzed reactions. These parameter changes collectively improve both yield and purity of the CL2A-SN-38 conjugates
Solution Approach 2:
The patent extracts and removes contaminating by-products through optimized purification procedures including reduced buffer washes and selective removal of triphenylphosphine, thereby increasing the purity of the final conjugate product
2Reliability
If standard conjugation protocols are used, then the process is straightforward, but toxicity is high and therapeutic efficacy is limited
Solution Approach 1:
The patent optimizes conjugation parameters including the use of maleimide moiety for antibody conjugation and controlled purification through tangential flow filtration. These changes enable better control over conjugate quality, reducing toxicity while maintaining therapeutic efficacy
Solution Approach 2:
The patent uses maleimide as an intermediary functional group that enables controlled conjugation between CL2A-SN-38 and antibodies. This intermediary approach allows for optimized conjugation conditions that reduce toxicity while preserving therapeutic activity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The protocol significantly enhances the yield and purity of CL2A-SN-38 conjugates, allowing for effective targeting and treatment of refractory diseases with reduced toxicity and improved bioavailability of the drug, enabling higher dosages and better therapeutic effects.
Implementation Method 1
using tetrabutylammonium fluoride for desilylation
Implementation Method 2
avoiding triphenylphosphine in copper-catalyzed reactions
Implementation Method 3
conjugation with antibodies or peptides using a maleimide moiety
Implementation Method 4
purification through tangential flow filtration
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6-8, alternatively 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme disclosed herein to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.